A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
Clinical trial NCT03164109 · COMPLETED
Trial details
- NCT number
- NCT03164109
- Sponsor
- Galera Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-18
- Primary completion
- 2017-10-13
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.